Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors
The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors. Nevertheless, only a fraction of solid tumors responds to this immunotherapy modality. Another modality of immuno...
Uložené v:
| Vydané v: | Hematology, Transfusion and Cell Therapy Ročník 43; číslo Suppl 2; s. S78 - S83 |
|---|---|
| Hlavní autori: | , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Elsevier España, S.L.U
01.11.2021
Sociedade Brasileira de Hematologia e Hemoterapia Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) Elsevier |
| Predmet: | |
| ISSN: | 2531-1379, 2531-1387, 2531-1387 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors. Nevertheless, only a fraction of solid tumors responds to this immunotherapy modality. Another modality of immunotherapy consists of employing cell-based therapy as an adoptive therapeutic modality. That involves distinct modalities of cellular therapies such as CAR T cells (chimeric antigen receptor T cell), TILs (tumor-infiltrating lymphocytes), and TCR T cells. Those treatments have proven effective in hematologic tumors and could have an impact in tumors that do not respond to checkpoint inhibitors. This review aims to outline the rationale, operation, clinical applicability, and results of adoptive cell therapy for patients with solid tumors. |
|---|---|
| AbstractList | The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors. Nevertheless, only a fraction of solid tumors responds to this immunotherapy modality. Another modality of immunotherapy consists of employing cell-based therapy as an adoptive therapeutic modality. That involves distinct modalities of cellular therapies such as CAR T cells (chimeric antigen receptor T cell), TILs (tumor-infiltrating lymphocytes), and TCR T cells. Those treatments have proven effective in hematologic tumors and could have an impact in tumors that do not respond to checkpoint inhibitors. This review aims to outline the rationale, operation, clinical applicability, and results of adoptive cell therapy for patients with solid tumors. The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors. Nevertheless, only a fraction of solid tumors responds to this immunotherapy modality. Another modality of immunotherapy consists of employing cell-based therapy as an adoptive therapeutic modality. That involves distinct modalities of cellular therapies such as CAR T cells (chimeric antigen receptor T cell), TILs (tumor-infiltrating lymphocytes), and TCR T cells. Those treatments have proven effective in hematologic tumors and could have an impact in tumors that do not respond to checkpoint inhibitors. This review aims to outline the rationale, operation, clinical applicability, and results of adoptive cell therapy for patients with solid tumors.The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors. Nevertheless, only a fraction of solid tumors responds to this immunotherapy modality. Another modality of immunotherapy consists of employing cell-based therapy as an adoptive therapeutic modality. That involves distinct modalities of cellular therapies such as CAR T cells (chimeric antigen receptor T cell), TILs (tumor-infiltrating lymphocytes), and TCR T cells. Those treatments have proven effective in hematologic tumors and could have an impact in tumors that do not respond to checkpoint inhibitors. This review aims to outline the rationale, operation, clinical applicability, and results of adoptive cell therapy for patients with solid tumors. ABSTRACT The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors. Nevertheless, only a fraction of solid tumors responds to this immunotherapy modality. Another modality of immunotherapy consists of employing cell-based therapy as an adoptive therapeutic modality. That involves distinct modalities of cellular therapies such as CAR T cells (chimeric antigen receptor T cell), TILs (tumor-infiltrating lymphocytes), and TCR T cells. Those treatments have proven effective in hematologic tumors and could have an impact in tumors that do not respond to checkpoint inhibitors. This review aims to outline the rationale, operation, clinical applicability, and results of adoptive cell therapy for patients with solid tumors. |
| Author | Avanzi, Mauro P. Nardo, Mirella Colli, Leandro M. Motta, Tatiane C. |
| AuthorAffiliation | Clinical Oncology, MD Anderson Cancer Center Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRPUSP) Neogene Therapeutics |
| AuthorAffiliation_xml | – name: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRPUSP) – name: Neogene Therapeutics – name: Clinical Oncology, MD Anderson Cancer Center |
| Author_xml | – sequence: 1 givenname: Mirella orcidid: 0000-0002-9396-7864 surname: Nardo fullname: Nardo, Mirella organization: Clinical Oncology, MD Anderson Cancer Center, Houston, USA – sequence: 2 givenname: Tatiane C. surname: Motta fullname: Motta, Tatiane C. organization: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRPUSP), Ribeirão Preto, SP, Brazil – sequence: 3 givenname: Leandro M. surname: Colli fullname: Colli, Leandro M. organization: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRPUSP), Ribeirão Preto, SP, Brazil – sequence: 4 givenname: Mauro P. orcidid: 0000-0002-2545-969X surname: Avanzi fullname: Avanzi, Mauro P. email: mauro.avanzi@yahoo.com.br organization: Neogene Therapeutics, Santa Monica, USA |
| BookMark | eNqFUtFuFCEUnZgaW2t_wCcefXBHYAYYGmPSbtQ2aWKi9ZkwzJ1dVgYqzNTs9_ig_9Efk3E3TaqJPhAucM_hwDlPiwMfPBTFc4JLggl_tSnXoxlLiikpsSwxIY-KI8oqsiBVIw7uayEPi5OUbIsrLBtWUfqkOKxqIesGk6Pi51lKwVh99-Pue0DnUSfrwEaNOkAXMOgxuLCy-uVfizBC1DdWI0DX-2oJbnI6omXwCXyaEgoercDDaI12bouG0NneQocMOJdK9BFuLXxDOuYGB6czgUPjeqbbIutRCs52aJyGENOz4nGvXYKT_XxcfH739np5sbj68P5yeXa1MKyS44JwA7KvOaWsbuu2ZbWgtOfAe9b2xAjdCQBBpKgM7qXAmFBJWkLrDhtg2lTHxeWOtwt6o26iHXTcqqCt-r0R4krt9SrOGNd9W-meirqvSFv3BgtDGOcNN02bucodVzIWXFCbMEWfxatPszlqNmf2D2PM8hBNBrzZAW6mdoDOgB-jdg9UPDzxdq1W4VY1HHNB6kzwYk8Qw9cJ0qgGm-bf1h7ClBRlUpJsfM1yK921mhhSitDfX0OwmiOmNmqOmJolKixVjlgGvd6BIFuQzYtqfpo30NkIubcL9t_w0z_gxlk_p-MLbP8H_gUr2fAy |
| Cites_doi | 10.1038/s41408-017-0023-x 10.3389/fimmu.2020.01314 10.1200/EDBK_156572 10.1038/s41598-017-11126-y 10.1182/blood-2011-12-400044 10.1038/s41591-018-0040-8 10.1056/NEJMoa1910607 10.1126/science.3489291 10.1126/scitranslmed.aaa0984 10.1158/0008-5472.CAN-10-2693 10.1098/rsob.180037 10.7150/ijbs.14405 10.1158/2326-6066.CIR-16-0376 10.3389/fimmu.2020.01217 10.1158/2326-6066.CIR-17-0314 10.1007/s13238-020-00707-9 10.1038/modpathol.2014.155 10.1126/science.aak9510 10.1158/1078-0432.CCR-14-2708 10.1007/s001099900042 10.1158/2159-8290.CD-18-0442 10.1126/science.aaa4967 10.3389/fimmu.2020.581301 10.21873/anticanres.14323 10.1182/blood.V128.22.3366.3366 10.1182/blood-2013-11-492231 10.3389/fimmu.2018.00947 10.1007/s10875-012-9689-9 10.1056/NEJMoa1609279 10.1200/JCO.2010.32.2537 10.1016/j.cell.2018.08.039 10.1056/NEJM198812223192527 10.1200/JCO.21.00612 10.1007/s00262-017-2007-x 10.1158/2326-6066.CIR-13-0170 10.1126/scitranslmed.3005930 10.1093/jnci/86.15.1159 10.1038/s41423-020-0504-x 10.1038/nrc971 10.1158/1078-0432.CCR-18-2722 10.1158/2159-8290.CD-15-1275 10.1200/JCO.2015.64.5929 10.1016/j.celrep.2018.04.051 10.1016/j.csbj.2016.09.003 10.1126/science.aad1253 10.1186/s40425-017-0274-x 10.1016/j.ymthe.2017.05.012 10.1126/science.1251102 10.3389/fimmu.2019.00128 10.1038/s41598-017-00462-8 10.1172/JCI87366 10.1172/JCI83416 10.3390/vaccines8040733 |
| ContentType | Journal Article |
| Copyright | 2021 Copyright © 2021. Published by Elsevier España, S.L.U. 2021 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. 2021 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
| Copyright_xml | – notice: 2021 – notice: Copyright © 2021. Published by Elsevier España, S.L.U. – notice: 2021 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. 2021 – notice: This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 5PM GPN DOA |
| DOI | 10.1016/j.htct.2021.09.011 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) SciELO Open Access: DOAJ - Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2531-1387 |
| EndPage | S83 |
| ExternalDocumentID | oai_doaj_org_article_6556afb3af274f31b4fc07c156686c8b S2531_13792021000500078 PMC8606714 10_1016_j_htct_2021_09_011 S2531137921001474 |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS M~E 6I. AAFTH AAYXX CITATION .1- .FO 7X8 AAEDW AALRI AAXUO AAYWO ABMAC ABXHO ACVFH ADBBV ADCNI ADVLN AEUPX AEXQZ AFPUW AFRHN AFTJW AIGII AITUG AJUYK AKBMS AKRWK AKYEP AMRAJ AOIJS APOWU BCNDV EBS FDB GROUPED_DOAJ HYE OK1 PGMZT ROL RPM RSC SSZ Z5R 5PM EJD GPN |
| ID | FETCH-LOGICAL-c539t-16ce9f462254b4bb54722f6e6f5bf1c7ad7ee71973c0f97001291b124d0ce5ac3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000721062300012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2531-1379 2531-1387 |
| IngestDate | Fri Oct 03 12:44:19 EDT 2025 Tue Nov 18 22:56:34 EST 2025 Thu Aug 21 18:33:36 EDT 2025 Thu Jul 10 18:28:47 EDT 2025 Thu Nov 13 04:24:01 EST 2025 Thu Jul 20 20:12:22 EDT 2023 Tue Aug 26 16:33:40 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 2 |
| Keywords | Checkpoint inhibitors Cell therapy Adoptive cell therapy Immunotherapy CAR-T cells |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. http://creativecommons.org/licenses/by-nc-nd/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c539t-16ce9f462254b4bb54722f6e6f5bf1c7ad7ee71973c0f97001291b124d0ce5ac3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-9396-7864 0000-0002-2545-969X |
| OpenAccessLink | https://doaj.org/article/6556afb3af274f31b4fc07c156686c8b |
| PMID | 34794801 |
| PQID | 2599180145 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6556afb3af274f31b4fc07c156686c8b scielo_journals_S2531_13792021000500078 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8606714 proquest_miscellaneous_2599180145 crossref_primary_10_1016_j_htct_2021_09_011 elsevier_sciencedirect_doi_10_1016_j_htct_2021_09_011 elsevier_clinicalkey_doi_10_1016_j_htct_2021_09_011 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-11-01 |
| PublicationDateYYYYMMDD | 2021-11-01 |
| PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Hematology, Transfusion and Cell Therapy |
| PublicationTitleAlternate | Hematol., Transfus. Cell Ther |
| PublicationYear | 2021 |
| Publisher | Elsevier España, S.L.U Sociedade Brasileira de Hematologia e Hemoterapia Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) Elsevier |
| Publisher_xml | – name: Elsevier España, S.L.U – name: Sociedade Brasileira de Hematologia e Hemoterapia – name: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) – name: Elsevier |
| References | Wang (bib0008) 1999; 77 Stevanović, Helman, Wunderlich (bib0018) 2019; 25 Hegde, Mukherjee, Grada (bib0037) 2016; 126 Shah, Fry (bib0053) 2019; 16 Ruella, Barrett, Kenderian (bib0034) 2016; 126 Zhang, Ye, Yuan, Luo, Jin, Qian (bib0003) 2016; 12 Velcheti, Schalper (bib0002) 2016; 35 Van Tine, Butler, Araujo (bib0051) 2019; 30 Lin, Du, Li, Zhu, Cui, Li (bib0012) 2020; 132 Corbière, Chapiro, Stroobant (bib0038) 2011; 71 Webb, Yuan, Meyer (bib0054) 2020 Endo, de Graaff, Ingram (bib0048) 2015; 28 Jazaeri, Zsiros, Amaria, Andrew, Robert, Edwards (bib0011) 2019; 15 Avanzi, Yeku, Li (bib0042) 2018; 23 Sasada, Kimura, Emi (bib0020) 2020; 40 Tosch, Bastien, Barraud (bib0039) 2017; 5 Keren, Bosse, Marquez (bib0021) 2018; 174 Pegram, Lee, Hayman (bib0041) 2012; 119 Rosenberg, Restifo (bib0022) 2015; 348 Robbins, Kassim, Tran (bib0050) 2015; 21 O'Rourke, Nasrallah, Desai (bib0031) 2017 Jul 19; 9 Krenciute, Prinzing, Yi (bib0032) 2017; 5 Martinez, Moon (bib0027) 2019; 10 Wang, Bhave, Yagita (bib0056) 2020; 11 Gupta, McElrath-Garza, Morton (bib0007) 2006 Majzner, Mackall (bib0033) 2018; 8 Van den Bulk, Verdegaal, De Miranda (bib0001) 2018; 8 Rupp, Schumann, Roybal (bib0059) 2017 Apr 7; 7 Ruella, Maus (bib0029) 2016; 14 Thomas, Al-Khadairi, Roelands (bib0046) 2018; 9 Stevanović, Pasetto, Helman (bib0016) 2017; 356 Presti, Buitenwerf, van Til, Nierkens (bib0057) 2020; 8 Heczey, Louis, Savoldo (bib0058) 2017; 25 Rosenberg, Yannelli, Yang, Topalian, Schwartzentruber, Weber (bib0010) 1994; 86 Wing, Fajardo, Posey (bib0026) 2018; 6 Brudno, Somerville, Shi (bib0024) 2016; 34 Maus, Grupp, Porter, June (bib0061) 2014; 123 Kosti, Maher, Arnold (bib0025) 2018; 9 Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676-80. Walseng, Köksal, Sektioglu (bib0045) 2017; 7 Liu, Marin, Banerjee (bib0052) 2020; 382 Hegde, Mukherji (bib0060) 2017; 66 Beatty, Haas, Maus (bib0040) 2014; 2 Zacharakis, Chinnasamy, Black (bib0017) 2018; 24 Sadelain, Rivière, Brentjens (bib0004) 2003; 3 Liu, Sun, Chen (bib0043) 2020 Sarnaik, Hamid, Khushalani (bib0019) 2021 Wilkie, Van Schalkwyk, Hobbs (bib0036) 2012; 32 Jackson, Brentjens (bib0030) 2015; 5 Robbins, Morgan, Feldman (bib0049) 2011; 29 Shah, Maatman, Hari, Johnson (bib0035) 2019; 9 Patel, Olivares, Singh (bib0047) 2016; 128 Brentjens, Davila, Riviere (bib0023) 2013; 5 Rooks, Garrett (bib0005) 2017; 176 Rosenberg, Spiess, Lafreniere (bib0006) 1986; 233 Tran, Robbins, Lu (bib0013) 2016; 375 Tran, Ahmadzadeh, Lu (bib0014) 2015; 350 Tran, Turcotte, Gros (bib0015) 2014; 344 Arcangeli, Falcone, Camisa (bib0044) 2020 Jun 19; 11 Mejstríková, Hrusak, Borowitz (bib0028) 2017; 7 Kabelitz, Serrano, Kouakanou (bib0055) 2020; 17 Corbière (10.1016/j.htct.2021.09.011_bib0038) 2011; 71 Rooks (10.1016/j.htct.2021.09.011_bib0005) 2017; 176 Keren (10.1016/j.htct.2021.09.011_bib0021) 2018; 174 Wang (10.1016/j.htct.2021.09.011_bib0056) 2020; 11 Wilkie (10.1016/j.htct.2021.09.011_bib0036) 2012; 32 Stevanović (10.1016/j.htct.2021.09.011_bib0016) 2017; 356 Zhang (10.1016/j.htct.2021.09.011_bib0003) 2016; 12 Sadelain (10.1016/j.htct.2021.09.011_bib0004) 2003; 3 Tosch (10.1016/j.htct.2021.09.011_bib0039) 2017; 5 Brentjens (10.1016/j.htct.2021.09.011_bib0023) 2013; 5 Sasada (10.1016/j.htct.2021.09.011_bib0020) 2020; 40 Lin (10.1016/j.htct.2021.09.011_bib0012) 2020; 132 Zacharakis (10.1016/j.htct.2021.09.011_bib0017) 2018; 24 Heczey (10.1016/j.htct.2021.09.011_bib0058) 2017; 25 Pegram (10.1016/j.htct.2021.09.011_bib0041) 2012; 119 Hegde (10.1016/j.htct.2021.09.011_bib0037) 2016; 126 Robbins (10.1016/j.htct.2021.09.011_bib0049) 2011; 29 Velcheti (10.1016/j.htct.2021.09.011_bib0002) 2016; 35 Kosti (10.1016/j.htct.2021.09.011_bib0025) 2018; 9 Majzner (10.1016/j.htct.2021.09.011_bib0033) 2018; 8 Maus (10.1016/j.htct.2021.09.011_bib0061) 2014; 123 Rosenberg (10.1016/j.htct.2021.09.011_bib0006) 1986; 233 Van Tine (10.1016/j.htct.2021.09.011_bib0051) 2019; 30 Hegde (10.1016/j.htct.2021.09.011_bib0060) 2017; 66 Patel (10.1016/j.htct.2021.09.011_bib0047) 2016; 128 Jazaeri (10.1016/j.htct.2021.09.011_bib0011) 2019; 15 Wang (10.1016/j.htct.2021.09.011_bib0008) 1999; 77 Sarnaik (10.1016/j.htct.2021.09.011_bib0019) 2021 Liu (10.1016/j.htct.2021.09.011_bib0043) 2020 Ruella (10.1016/j.htct.2021.09.011_bib0029) 2016; 14 Stevanović (10.1016/j.htct.2021.09.011_bib0018) 2019; 25 Tran (10.1016/j.htct.2021.09.011_bib0013) 2016; 375 Liu (10.1016/j.htct.2021.09.011_bib0052) 2020; 382 Jackson (10.1016/j.htct.2021.09.011_bib0030) 2015; 5 Rosenberg (10.1016/j.htct.2021.09.011_bib0010) 1994; 86 Webb (10.1016/j.htct.2021.09.011_bib0054) 2020 Endo (10.1016/j.htct.2021.09.011_bib0048) 2015; 28 Ruella (10.1016/j.htct.2021.09.011_bib0034) 2016; 126 Brudno (10.1016/j.htct.2021.09.011_bib0024) 2016; 34 Thomas (10.1016/j.htct.2021.09.011_bib0046) 2018; 9 Van den Bulk (10.1016/j.htct.2021.09.011_bib0001) 2018; 8 Gupta (10.1016/j.htct.2021.09.011_bib0007) 2006 Mejstríková (10.1016/j.htct.2021.09.011_bib0028) 2017; 7 Beatty (10.1016/j.htct.2021.09.011_bib0040) 2014; 2 Robbins (10.1016/j.htct.2021.09.011_bib0050) 2015; 21 Tran (10.1016/j.htct.2021.09.011_bib0014) 2015; 350 Arcangeli (10.1016/j.htct.2021.09.011_bib0044) 2020; 11 Shah (10.1016/j.htct.2021.09.011_bib0053) 2019; 16 Rupp (10.1016/j.htct.2021.09.011_bib0059) 2017; 7 Rosenberg (10.1016/j.htct.2021.09.011_bib0022) 2015; 348 Shah (10.1016/j.htct.2021.09.011_bib0035) 2019; 9 Krenciute (10.1016/j.htct.2021.09.011_bib0032) 2017; 5 Wing (10.1016/j.htct.2021.09.011_bib0026) 2018; 6 Kabelitz (10.1016/j.htct.2021.09.011_bib0055) 2020; 17 Presti (10.1016/j.htct.2021.09.011_bib0057) 2020; 8 Avanzi (10.1016/j.htct.2021.09.011_bib0042) 2018; 23 O'Rourke (10.1016/j.htct.2021.09.011_bib0031) 2017; 9 10.1016/j.htct.2021.09.011_bib0009 Tran (10.1016/j.htct.2021.09.011_bib0015) 2014; 344 Martinez (10.1016/j.htct.2021.09.011_bib0027) 2019; 10 Walseng (10.1016/j.htct.2021.09.011_bib0045) 2017; 7 Velcheti, V; Schalper, PK 2016; 35 Maus M, V; Grupp, SA; Porter, DL; June, CH 2014; 123 Shah, NN; Maatman, T; Hari, P; Johnson, B 2019; 9 Robbins, PF; Kassim, SH; Tran, TL; Crystal, JS; Morgan, RA; Feldman, SA 2015; 21 Rosenberg, SA; Yannelli, JR; Yang, JC; Topalian, SL; Schwartzentruber, DJ; Weber, JS 1994; 86 Lin, B; Du, L; Li, H; Zhu, X; Cui, L; Li, X 2020; 132 Shah, NN; Fry, TJ 2019; 16 Lo, Presti V; Buitenwerf, F; van Til, NP; Nierkens, S 2020; 8 Van den Bulk, J; Verdegaal, EM; De Miranda, NF 2018; 8 Avanzi, MP; Yeku, O; Li, X 2018; 23 Kabelitz, D; Serrano, R; Kouakanou, L 2020; 17 Liu, E; Marin, D; Banerjee, P 2020; 382 Tran, E; Robbins, PF; Lu, Y-C; Prickett, TD; Gartner, JJ; Jia, L 2016; 375 Stevanovic, S; Helman, SR; Wunderlich, JR; Langhan, MM; Doran, SL; Kwong, MLM 2019; 25 Mejstríkova, E; Hrusak, O; Borowitz M, .J; Whitlock, JA; Brethon, B; Trippett, TM 2017; 7 Wang, Y; Bhave, MS; Yagita, H 2020; 11 Ruella, M; Barrett, DM; Kenderian, SS; Shestova, O; Hofmann, TJ; Perazzelli, J 2016; 126 Jackson, HJ; Brentjens, RJ 2015; 5 Keren, L; Bosse, M; Marquez, D; Angoshtari, R; Jain, S; Varma, S 2018; 174 Tran, E; Turcotte, S; Gros, A; Robbins, PF; Lu, YC; Dudley, ME 2014; 344 Robbins, PF; Morgan, RA; Feldman, SA; Yang, JC; Sherry, RM; Dudley, ME 2011; 29 Rosenberg, SA; Packard, BS; Aebersold, PM; Solomon, D; Topalian, SL; Toy, ST 1988; 319 Corbiere, V; Chapiro, J; Stroobant, V; Ma, W; Lurquin, C; Leth e, B 2011; 71 Endo, M; de Graaff, MA; Ingram, DR; Lim, S; Lev, DC; BriaireeBruijn, IH 2015; 28 Sasada, S; Kimura, Y; Emi, A; Masumoto, N; Kadoya, T; Arihiro, K 2020; 40 Brudno, JN; Somerville, RP; Shi, V; Rose, JJ; Halverson, DC; Fowler, DH 2016; 34 Wilkie, S; Van Schalkwyk, MC; Hobbs, S; Davies, DM; van der Stegen, SJ; Pereira, AC 2012; 32 Rooks, MG; Garrett, WS 2017; 176 Brentjens, RJ; Davila, ML; Riviere, I; Park, J; Wang, X; Cowell, LG 2013; 5 Heczey, A; Louis, CU; Savoldo, B; Dakhova, O; Durett, A; Grilley, B 2017; 25 Liu, Q; Sun, Z; Chen, L 2020 Rosenberg, SA; Restifo, NP 2015; 348 Thomas, R; Al-Khadairi, G; Roelands, J; Hendrickx, W; Dermime, S; Bedognetti, D 2018; 9 Stevanovic, S; Pasetto, A; Helman, SR; Gartner, JJ; Prickett, TD; Howie, B 2017; 356 Ruella, M; Maus, MV 2016; 14 Beatty, GL; Haas, AR; Maus, MV; Torigian, DA; Soulen, MC; Plesa, G 2014; 2 Tosch, C; Bastien, B; Barraud, L; Grellier, B; Nourtier, V; Gantzer, M 2017; 5 Tran, E; Ahmadzadeh, M; Lu, YC; Gros, A; Turcotte, S; Robbins, PF 2015; 350 Sadelain, M; Rivière, I; Brentjens, R 2003; 3 Zacharakis, N; Chinnasamy, H; Black, M; Xu, H; Lu, YC; Zheng, Z 2018; 24 O'Rourke, DM; Nasrallah, MP; Desai, A; Melenhorst, JJ; Mansfield, K; Morrissette, JJD 2017; 9 Van Tine, BA; Butler, MO; Araujo, D 2019; 30 Krenciute, G; Prinzing, BL; Yi, Z; Yi, Z; Wu, MF; Liu, H; Dotti, G 2017; 5 Arcangeli, S; Falcone, L; Camisa, B 2020; 11 Hegde, UP; Mukherji, B 2017; 66 Rosenberg, SA; Spiess, P; Lafreniere, R 1986; 233 Majzner, RG; Mackall, CL 2018; 8 Rupp, LJ; Schumann, K; Roybal, KT; Gate, RE; Ye, CJ; Lim, WA 2017; 7 Hegde, M; Mukherjee, M; Grada, Z; Pignata, A; Landi, D; Navai, SA 2016; 126 Pegram, HJ; Lee, JC; Hayman, EG 2012; 119 Patel, K; Olivares, S; Singh, H; Hurton, LV; Huls, MH; Qazilbash, MH 2016; 128 Wang, RF 1999; 77 Gupta, RK; McElrath-Garza, AM; Morton, DL Sarnaik, AA; Hamid, O; Khushalani, NI 2021 Martinez, M; Moon, EK 2019; 10 Wing, A; Fajardo, CA; Posey, AD; Shaw, C; Da, T; Young, RM 2018; 6 Walseng, E; Koksal, H; Sektioglu, IM; Fä ne, A; Skorstad, G; Kvalheim, G 2017; 7 Zhang, H; Ye, ZL; Yuan, ZG; Luo, ZQ; Jin, HJ; Qian, QJ 2016; 12 Kosti, P; Maher, J; Arnold, JN 2018; 9 Jazaeri, AA; Zsiros, E; Amaria, RN; Andrew, SArtz; Robert, P; Edwards, RM 2019 Webb, TJ; Yuan, W; Meyer, E 2020 |
| References_xml | – volume: 11 start-page: 1217 year: 2020 Jun 19 ident: bib0044 article-title: Next-generation manufacturing protocols enriching T SCM CAR T cells can overcome disease-specific T cell defects in cancer patients publication-title: Front Immunol – volume: 382 start-page: 545 year: 2020 end-page: 553 ident: bib0052 article-title: Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors publication-title: N Engl J Med – volume: 23 start-page: 2130 year: 2018 end-page: 2141 ident: bib0042 article-title: Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system publication-title: Cell Rep – volume: 126 start-page: 3036 year: 2016 end-page: 3052 ident: bib0037 article-title: Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape publication-title: J Clin Invest – volume: 30 start-page: v683 year: 2019 end-page: v709 ident: bib0051 article-title: ADP-A2M4 (MAGE-A4) in patients with Synovial Sarcoma publication-title: Ann Oncol – volume: 123 start-page: 2625 year: 2014 end-page: 2635 ident: bib0061 article-title: Antibody-modified T cells: CARs take the front seat for hematologic malignancies publication-title: Blood – volume: 11 year: 2020 ident: bib0056 article-title: Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 blockade synergize to reduce tumor development in a preclinical model of colon cancer publication-title: Front Immunol – volume: 348 start-page: 62 year: 2015 end-page: 68 ident: bib0022 article-title: Adoptive cell transfer as personalized immunotherapy for human cancer publication-title: Science (80-) – volume: 29 start-page: 917 year: 2011 end-page: 924 ident: bib0049 article-title: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 publication-title: J Clin Oncol – volume: 7 start-page: 659 year: 2017 ident: bib0028 article-title: CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment publication-title: Blood Cancer J – volume: 15 year: 2019 ident: bib0011 article-title: Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma publication-title: J Clin Oncol – volume: 375 start-page: 2255 year: 2016 end-page: 2262 ident: bib0013 article-title: T-Cell transfer therapy targeting mutant KRAS in cancer publication-title: N Engl J Med – volume: 14 start-page: 357 year: 2016 end-page: 362 ident: bib0029 article-title: Catch me if you can: leukemia Escape after CD19-Directed T Cell Immunotherapies publication-title: Comput Struct Biotechnol J – volume: 5 start-page: 70 year: 2017 ident: bib0039 article-title: Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC publication-title: J Immunother Cancer – volume: 2 start-page: 112 year: 2014 end-page: 120 ident: bib0040 article-title: Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies publication-title: Cancer Immunol Res – volume: 119 start-page: 4133 year: 2012 end-page: 4141 ident: bib0041 article-title: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning publication-title: Blood – volume: 126 start-page: 3814 year: 2016 end-page: 3826 ident: bib0034 article-title: Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies publication-title: J Clin Investig – volume: 17 start-page: 925 year: 2020 end-page: 939 ident: bib0055 article-title: Cancer immunotherapy with γδ T cells: many paths ahead of us publication-title: Cell Mol Immunol – volume: 132 year: 2020 ident: bib0012 article-title: Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully publication-title: Biomed Pharmacother – volume: 174 start-page: 1373 year: 2018 end-page: 1387.e19 ident: bib0021 article-title: A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging publication-title: Cell – volume: 66 start-page: 1113 year: 2017 end-page: 1121 ident: bib0060 article-title: Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies publication-title: Cancer Immunol Immunother – reference: Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676-80. – volume: 9 start-page: 947 year: 2018 ident: bib0046 article-title: NY-ESO-1 based immunotherapy of cancer: current perspectives publication-title: Front Immunol – volume: 34 start-page: 1112 year: 2016 end-page: 1121 ident: bib0024 article-title: Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease publication-title: J Clin Oncol – volume: 128 start-page: 3366 year: 2016 ident: bib0047 article-title: Combination Immunotherapy with NY-ESO-1-Specific CAR+ T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect publication-title: Blood. – volume: 7 start-page: 1 year: 2017 end-page: 10 ident: bib0045 article-title: A TCR-based chimeric antigen receptor publication-title: Sci Rep. – volume: 9 start-page: eaaa0984 year: 2017 Jul 19 ident: bib0031 article-title: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma publication-title: Sci Transl Med – year: 2021 ident: bib0019 article-title: Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma publication-title: J Clin Oncol – volume: 5 start-page: 571 year: 2017 end-page: 581 ident: bib0032 article-title: Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants publication-title: Cancer Immunol Res – volume: 9 start-page: 1 year: 2019 end-page: 7 ident: bib0035 article-title: Multi targeted CAR-T cell therapies for B-cell malignancies publication-title: Front Oncol – volume: 3 start-page: 35 year: 2003 end-page: 45 ident: bib0004 article-title: Targeting tumours with genetically enhanced T lymphocytes publication-title: Nat Rev Cancer – volume: 176 start-page: 139 year: 2017 end-page: 148 ident: bib0005 article-title: Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know publication-title: Physiol Behav – volume: 24 start-page: 724 year: 2018 end-page: 730 ident: bib0017 article-title: Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer publication-title: Nat Med – volume: 6 start-page: 605 year: 2018 end-page: 616 ident: bib0026 article-title: Improving CART-cell therapy of solid tumors with oncolytic virus–driven production of a bispecific T-cell engager publication-title: Cancer Immunol Res – volume: 77 start-page: 640 year: 1999 end-page: 655 ident: bib0008 article-title: Human tumor antigens: implications for cancer vaccine development publication-title: J Mol Med – volume: 86 start-page: 1159 year: 1994 end-page: 1166 ident: bib0010 article-title: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 publication-title: J Natl Cancer Inst – volume: 356 start-page: 200 year: 2017 end-page: 205 ident: bib0016 article-title: Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer publication-title: Science – volume: 5 start-page: 1238 year: 2015 end-page: 1240 ident: bib0030 article-title: Overcoming antigen escape with CAR T-cell therapy publication-title: Cancer Discov – volume: 71 start-page: 1253 year: 2011 end-page: 1262 ident: bib0038 article-title: Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases publication-title: Cancer Res – start-page: 549 year: 2020 end-page: 564 ident: bib0043 article-title: Memory T cells: strategies for optimizing tumor immunotherapy publication-title: Protein Cell – volume: 8 start-page: 1 year: 2020 end-page: 22 ident: bib0057 article-title: Gene augmentation and editing to improve tcr engineered t cell therapy against solid tumors publication-title: Vaccines – volume: 9 year: 2018 ident: bib0025 article-title: Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors publication-title: Front Immunol – volume: 233 start-page: 1318 year: 1986 end-page: 1321 ident: bib0006 article-title: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes publication-title: Science (80-) – volume: 40 start-page: 3395 year: 2020 end-page: 3400 ident: bib0020 article-title: Tumor-infiltrating lymphocyte score based on FDG PET/CT for predicting the effect of neoadjuvant chemotherapy in breast cancer publication-title: Anticancer Res – volume: 25 start-page: 1486 year: 2019 end-page: 1493 ident: bib0018 article-title: A Phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus–associated epithelial cancers publication-title: Clin Cancer Res – volume: 12 start-page: 718 year: 2016 end-page: 729 ident: bib0003 article-title: New strategies for the treatment of solid tumors with CAR-T cells publication-title: Int J Biol Sci – start-page: 619 year: 2006 end-page: 631 ident: bib0007 article-title: Role of melanoma-associated antigens publication-title: From Melanocytes to Melanoma Progress to Malig – volume: 7 start-page: 737 year: 2017 Apr 7 ident: bib0059 article-title: CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells publication-title: Sci Rep – volume: 25 start-page: 2214 year: 2017 end-page: 2224 ident: bib0058 article-title: CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma publication-title: Mol Ther – volume: 8 start-page: 1 year: 2018 end-page: 10 ident: bib0001 article-title: Cancer immunotherapy: broadening the scope of targetable tumours publication-title: Open Biol – volume: 21 start-page: 1019 year: 2015 end-page: 1027 ident: bib0050 article-title: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response publication-title: Clin Cancer Res – volume: 5 start-page: 177ra38 year: 2013 ident: bib0023 article-title: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia publication-title: Sci Transl Med – volume: 10 start-page: 128 year: 2019 ident: bib0027 article-title: CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment publication-title: Front Immunol – volume: 32 start-page: 1059 year: 2012 end-page: 1070 ident: bib0036 article-title: Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling publication-title: J Clin Immunol – year: 2020 ident: bib0054 article-title: NKT Cells in cancer immunotherapy publication-title: Front. Immunol. – volume: 16 start-page: 372 year: 2019 end-page: 385 ident: bib0053 article-title: Mechanisms of resistance to CAR T cell therapy publication-title: Nat Rev Clin Oncol – volume: 35 start-page: 298 year: 2016 end-page: 308 ident: bib0002 article-title: Overview. Basic overview of current immunotherapy approaches in cancer publication-title: Am Soc Clin Oncol Educ B – volume: 344 start-page: 641 year: 2014 end-page: 645 ident: bib0015 article-title: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer publication-title: Science – volume: 28 start-page: 587 year: 2015 end-page: 595 ident: bib0048 article-title: NY-ESO-1 (CTAG1B) expression in mesenchymal tumors publication-title: Mod Pathol – volume: 350 start-page: 1387 year: 2015 end-page: 1390 ident: bib0014 article-title: Immunogenicity of somatic mutations in human gastrointestinal cancers publication-title: Science – volume: 8 start-page: 1219 year: 2018 end-page: 1226 ident: bib0033 article-title: Tumor antigen escape from car t-cell therapy publication-title: Cancer Discov – volume: 7 start-page: 659 issue: 12 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0028 article-title: CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment publication-title: Blood Cancer J doi: 10.1038/s41408-017-0023-x – year: 2020 ident: 10.1016/j.htct.2021.09.011_bib0054 article-title: NKT Cells in cancer immunotherapy publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.01314 – volume: 35 start-page: 298 year: 2016 ident: 10.1016/j.htct.2021.09.011_bib0002 article-title: Overview. Basic overview of current immunotherapy approaches in cancer publication-title: Am Soc Clin Oncol Educ B doi: 10.1200/EDBK_156572 – volume: 7 start-page: 1 issue: 1 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0045 article-title: A TCR-based chimeric antigen receptor publication-title: Sci Rep. doi: 10.1038/s41598-017-11126-y – volume: 119 start-page: 4133 issue: 18 year: 2012 ident: 10.1016/j.htct.2021.09.011_bib0041 article-title: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning publication-title: Blood doi: 10.1182/blood-2011-12-400044 – volume: 24 start-page: 724 issue: 6 year: 2018 ident: 10.1016/j.htct.2021.09.011_bib0017 article-title: Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer publication-title: Nat Med doi: 10.1038/s41591-018-0040-8 – volume: 382 start-page: 545 year: 2020 ident: 10.1016/j.htct.2021.09.011_bib0052 article-title: Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors publication-title: N Engl J Med doi: 10.1056/NEJMoa1910607 – volume: 233 start-page: 1318 issue: 4770 year: 1986 ident: 10.1016/j.htct.2021.09.011_bib0006 article-title: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes publication-title: Science (80-) doi: 10.1126/science.3489291 – start-page: 619 year: 2006 ident: 10.1016/j.htct.2021.09.011_bib0007 article-title: Role of melanoma-associated antigens – volume: 9 start-page: eaaa0984 issue: 399 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0031 article-title: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaa0984 – volume: 71 start-page: 1253 issue: 4 year: 2011 ident: 10.1016/j.htct.2021.09.011_bib0038 article-title: Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2693 – volume: 8 start-page: 1 issue: 6 year: 2018 ident: 10.1016/j.htct.2021.09.011_bib0001 article-title: Cancer immunotherapy: broadening the scope of targetable tumours publication-title: Open Biol doi: 10.1098/rsob.180037 – volume: 12 start-page: 718 issue: 6 year: 2016 ident: 10.1016/j.htct.2021.09.011_bib0003 article-title: New strategies for the treatment of solid tumors with CAR-T cells publication-title: Int J Biol Sci doi: 10.7150/ijbs.14405 – volume: 5 start-page: 571 issue: 7 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0032 article-title: Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-16-0376 – volume: 11 start-page: 1217 year: 2020 ident: 10.1016/j.htct.2021.09.011_bib0044 article-title: Next-generation manufacturing protocols enriching T SCM CAR T cells can overcome disease-specific T cell defects in cancer patients publication-title: Front Immunol doi: 10.3389/fimmu.2020.01217 – volume: 6 start-page: 605 issue: 5 year: 2018 ident: 10.1016/j.htct.2021.09.011_bib0026 article-title: Improving CART-cell therapy of solid tumors with oncolytic virus–driven production of a bispecific T-cell engager publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-17-0314 – start-page: 549 issue: 8 year: 2020 ident: 10.1016/j.htct.2021.09.011_bib0043 article-title: Memory T cells: strategies for optimizing tumor immunotherapy publication-title: Protein Cell doi: 10.1007/s13238-020-00707-9 – volume: 28 start-page: 587 issue: 4 year: 2015 ident: 10.1016/j.htct.2021.09.011_bib0048 article-title: NY-ESO-1 (CTAG1B) expression in mesenchymal tumors publication-title: Mod Pathol doi: 10.1038/modpathol.2014.155 – volume: 356 start-page: 200 issue: 6334 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0016 article-title: Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer publication-title: Science doi: 10.1126/science.aak9510 – volume: 21 start-page: 1019 issue: 5 year: 2015 ident: 10.1016/j.htct.2021.09.011_bib0050 article-title: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-2708 – volume: 30 start-page: v683 issue: suppl_5 year: 2019 ident: 10.1016/j.htct.2021.09.011_bib0051 article-title: ADP-A2M4 (MAGE-A4) in patients with Synovial Sarcoma publication-title: Ann Oncol – volume: 77 start-page: 640 issue: 9 year: 1999 ident: 10.1016/j.htct.2021.09.011_bib0008 article-title: Human tumor antigens: implications for cancer vaccine development publication-title: J Mol Med doi: 10.1007/s001099900042 – volume: 8 start-page: 1219 issue: 10 year: 2018 ident: 10.1016/j.htct.2021.09.011_bib0033 article-title: Tumor antigen escape from car t-cell therapy publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-18-0442 – volume: 348 start-page: 62 issue: 6230 year: 2015 ident: 10.1016/j.htct.2021.09.011_bib0022 article-title: Adoptive cell transfer as personalized immunotherapy for human cancer publication-title: Science (80-) doi: 10.1126/science.aaa4967 – volume: 11 year: 2020 ident: 10.1016/j.htct.2021.09.011_bib0056 article-title: Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 blockade synergize to reduce tumor development in a preclinical model of colon cancer publication-title: Front Immunol doi: 10.3389/fimmu.2020.581301 – volume: 40 start-page: 3395 issue: 6 year: 2020 ident: 10.1016/j.htct.2021.09.011_bib0020 article-title: Tumor-infiltrating lymphocyte score based on FDG PET/CT for predicting the effect of neoadjuvant chemotherapy in breast cancer publication-title: Anticancer Res doi: 10.21873/anticanres.14323 – volume: 128 start-page: 3366 issue: 22 year: 2016 ident: 10.1016/j.htct.2021.09.011_bib0047 article-title: Combination Immunotherapy with NY-ESO-1-Specific CAR+ T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect publication-title: Blood. doi: 10.1182/blood.V128.22.3366.3366 – volume: 123 start-page: 2625 issue: 17 year: 2014 ident: 10.1016/j.htct.2021.09.011_bib0061 article-title: Antibody-modified T cells: CARs take the front seat for hematologic malignancies publication-title: Blood doi: 10.1182/blood-2013-11-492231 – volume: 9 start-page: 947 year: 2018 ident: 10.1016/j.htct.2021.09.011_bib0046 article-title: NY-ESO-1 based immunotherapy of cancer: current perspectives publication-title: Front Immunol doi: 10.3389/fimmu.2018.00947 – volume: 32 start-page: 1059 issue: 5 year: 2012 ident: 10.1016/j.htct.2021.09.011_bib0036 article-title: Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling publication-title: J Clin Immunol doi: 10.1007/s10875-012-9689-9 – volume: 375 start-page: 2255 issue: 23 year: 2016 ident: 10.1016/j.htct.2021.09.011_bib0013 article-title: T-Cell transfer therapy targeting mutant KRAS in cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1609279 – volume: 29 start-page: 917 issue: 7 year: 2011 ident: 10.1016/j.htct.2021.09.011_bib0049 article-title: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.32.2537 – volume: 132 issue: August year: 2020 ident: 10.1016/j.htct.2021.09.011_bib0012 article-title: Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully publication-title: Biomed Pharmacother – volume: 174 start-page: 1373 issue: 6 year: 2018 ident: 10.1016/j.htct.2021.09.011_bib0021 article-title: A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging publication-title: Cell doi: 10.1016/j.cell.2018.08.039 – ident: 10.1016/j.htct.2021.09.011_bib0009 doi: 10.1056/NEJM198812223192527 – year: 2021 ident: 10.1016/j.htct.2021.09.011_bib0019 article-title: Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.21.00612 – volume: 9 start-page: 1 issue: MAR year: 2019 ident: 10.1016/j.htct.2021.09.011_bib0035 article-title: Multi targeted CAR-T cell therapies for B-cell malignancies publication-title: Front Oncol – volume: 66 start-page: 1113 issue: 9 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0060 article-title: Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-017-2007-x – volume: 2 start-page: 112 issue: 2 year: 2014 ident: 10.1016/j.htct.2021.09.011_bib0040 article-title: Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-13-0170 – volume: 9 issue: MAY year: 2018 ident: 10.1016/j.htct.2021.09.011_bib0025 article-title: Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors publication-title: Front Immunol – volume: 5 start-page: 177ra38 issue: 177 year: 2013 ident: 10.1016/j.htct.2021.09.011_bib0023 article-title: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3005930 – volume: 16 start-page: 372 year: 2019 ident: 10.1016/j.htct.2021.09.011_bib0053 article-title: Mechanisms of resistance to CAR T cell therapy publication-title: Nat Rev Clin Oncol – volume: 86 start-page: 1159 issue: 15 year: 1994 ident: 10.1016/j.htct.2021.09.011_bib0010 article-title: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/86.15.1159 – volume: 17 start-page: 925 issue: 9 year: 2020 ident: 10.1016/j.htct.2021.09.011_bib0055 article-title: Cancer immunotherapy with γδ T cells: many paths ahead of us publication-title: Cell Mol Immunol doi: 10.1038/s41423-020-0504-x – volume: 3 start-page: 35 issue: 1 year: 2003 ident: 10.1016/j.htct.2021.09.011_bib0004 article-title: Targeting tumours with genetically enhanced T lymphocytes publication-title: Nat Rev Cancer doi: 10.1038/nrc971 – volume: 25 start-page: 1486 issue: 5 year: 2019 ident: 10.1016/j.htct.2021.09.011_bib0018 article-title: A Phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus–associated epithelial cancers publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-2722 – volume: 5 start-page: 1238 issue: 12 year: 2015 ident: 10.1016/j.htct.2021.09.011_bib0030 article-title: Overcoming antigen escape with CAR T-cell therapy publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-1275 – volume: 176 start-page: 139 issue: 3 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0005 article-title: Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know publication-title: Physiol Behav – volume: 34 start-page: 1112 issue: 10 year: 2016 ident: 10.1016/j.htct.2021.09.011_bib0024 article-title: Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease publication-title: J Clin Oncol doi: 10.1200/JCO.2015.64.5929 – volume: 23 start-page: 2130 issue: 7 year: 2018 ident: 10.1016/j.htct.2021.09.011_bib0042 article-title: Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system publication-title: Cell Rep doi: 10.1016/j.celrep.2018.04.051 – volume: 14 start-page: 357 year: 2016 ident: 10.1016/j.htct.2021.09.011_bib0029 article-title: Catch me if you can: leukemia Escape after CD19-Directed T Cell Immunotherapies publication-title: Comput Struct Biotechnol J doi: 10.1016/j.csbj.2016.09.003 – volume: 350 start-page: 1387 issue: 6266 year: 2015 ident: 10.1016/j.htct.2021.09.011_bib0014 article-title: Immunogenicity of somatic mutations in human gastrointestinal cancers publication-title: Science doi: 10.1126/science.aad1253 – volume: 5 start-page: 70 issue: 1 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0039 article-title: Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0274-x – volume: 25 start-page: 2214 issue: 9 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0058 article-title: CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma publication-title: Mol Ther doi: 10.1016/j.ymthe.2017.05.012 – volume: 15 year: 2019 ident: 10.1016/j.htct.2021.09.011_bib0011 article-title: Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma publication-title: J Clin Oncol – volume: 344 start-page: 641 issue: 6184 year: 2014 ident: 10.1016/j.htct.2021.09.011_bib0015 article-title: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer publication-title: Science doi: 10.1126/science.1251102 – volume: 10 start-page: 128 year: 2019 ident: 10.1016/j.htct.2021.09.011_bib0027 article-title: CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment publication-title: Front Immunol doi: 10.3389/fimmu.2019.00128 – volume: 7 start-page: 737 issue: 1 year: 2017 ident: 10.1016/j.htct.2021.09.011_bib0059 article-title: CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells publication-title: Sci Rep doi: 10.1038/s41598-017-00462-8 – volume: 126 start-page: 3814 issue: 10 year: 2016 ident: 10.1016/j.htct.2021.09.011_bib0034 article-title: Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies publication-title: J Clin Investig doi: 10.1172/JCI87366 – volume: 126 start-page: 3036 issue: 8 year: 2016 ident: 10.1016/j.htct.2021.09.011_bib0037 article-title: Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape publication-title: J Clin Invest doi: 10.1172/JCI83416 – volume: 8 start-page: 1 issue: 4 year: 2020 ident: 10.1016/j.htct.2021.09.011_bib0057 article-title: Gene augmentation and editing to improve tcr engineered t cell therapy against solid tumors publication-title: Vaccines doi: 10.3390/vaccines8040733 – volume: 7 start-page: 659 issue: 12 year: 2017 article-title: CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment publication-title: Blood Cancer J – start-page: 549 issue: 8 year: 2020 end-page: 64 article-title: Memory T cells: strategies for optimizing tumor immunotherapy publication-title: Protein Cell – volume: 350 start-page: 1387 issue: 6266 year: 2015 end-page: 90 article-title: Immunogenicity of somatic mutations in human gastrointestinal cancers publication-title: Science – volume: 35 start-page: 298 year: 2016 end-page: 308 article-title: Overview publication-title: Basic overview of currentimmunotherapy approaches in cancer. Am Soc Clin Oncol Educ B – volume: 233 start-page: 1318 issue: 4770 year: 1986 end-page: 21 article-title: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes publication-title: Science (80-) – volume: 174 start-page: 1373 issue: 6 year: 2018 end-page: 1387.e19 article-title: A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging publication-title: Cell – volume: 7 start-page: 1 issue: 1 year: 2017 end-page: 10 article-title: A TCR-based chimeric antigen receptor publication-title: Sci Rep – start-page: JCO2100612 year: 2021 article-title: Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma publication-title: J Clin Oncol – volume: 25 start-page: 2214 issue: 9 year: 2017 end-page: 24 article-title: CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma publication-title: Mol Ther – volume: 11 start-page: 581301 year: 2020 article-title: Natural Killer T-Cell Agonista-Galactosylceramide and PD-1 blockade synergize to reduce tumor development in a preclinical model of colon cancer publication-title: Front Immunol – volume: 9 issue: MAY year: 2018 article-title: Perspectives on chimeric antigenreceptor T-cell immunotherapy for solid tumors publication-title: Front Immunol – volume: 123 start-page: 2625 issue: 17 year: 2014 end-page: 35 article-title: Antibody-modified T cells: CARs take the front seat for hematologic malignancies publication-title: Blood – volume: 8 start-page: 1219 issue: 10 year: 2018 end-page: 26 article-title: Tumor antigen escape from car t-celltherapy publication-title: Cancer Discov – volume: 24 start-page: 724 issue: 6 year: 2018 end-page: 30 article-title: Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer publication-title: Nat Med – volume: 66 start-page: 1113 issue: 9 year: 2017 end-page: 21 article-title: Current status of chimeric antigenreceptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies publication-title: Cancer Immunol Immunother – volume: 28 start-page: 587 issue: 4 year: 2015 end-page: 95 article-title: NY-ESO-1 (CTAG1B) expression in mesenchymal tumors publication-title: Mod Pathol – volume: 9 start-page: 1 issue: MAR year: 2019 end-page: 7 article-title: Multi targeted CAR-Tcell therapies for B-cell malignancies publication-title: Front Oncol – volume: 3 start-page: 35 issue: 1 year: 2003 end-page: 45 article-title: Targeting tumours with genetically enhanced T lymphocytes publication-title: Nat Rev Cancer – volume: 356 start-page: 200 issue: 6334 year: 2017 end-page: 5 article-title: Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer publication-title: Science – volume: 5 start-page: 70 issue: 1 year: 2017 article-title: Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC publication-title: J Immunother Cancer – volume: 5 start-page: 1238 issue: 12 year: 2015 end-page: 40 article-title: Overcoming antigen escape with CART-cell therapy publication-title: Cancer Discov – volume: 128 start-page: 3366 issue: 22 year: 2016 article-title: Combination Immunotherapy with NY-ESO-1-Specific CAR+ T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect publication-title: Blood – year: 2020 article-title: NKT Cells in cancer immunotherapy publication-title: Front. Immunol – volume: 382 start-page: 545 year: 2020 end-page: 53 article-title: Use of CAR-transduced naturalkiller cells in CD19-positive lymphoid tumors publication-title: N Engl J Med – volume: 8 start-page: 1 issue: 6 year: 2018 end-page: 10 article-title: Cancer immunotherapy: broadening the scope of targetable tumours publication-title: Open Biol – volume: 9 start-page: 947 year: 2018 article-title: NY-ESO-1 based immunotherapy of cancer: current perspectives publication-title: Front Immunol – volume: 23 start-page: 2130 issue: 7 year: 2018 end-page: 41 article-title: Engineered tumor-targeted T cellsmediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system publication-title: Cell Rep – volume: 16 start-page: 372 year: 2019 end-page: 85 article-title: Mechanisms of resistance to CAR T cell therapy publication-title: Nat Rev Clin Oncol – volume: 375 start-page: 2255 issue: 23 year: 2016 end-page: 62 article-title: TCell transfer therapy targeting mutant KRAS in cancer publication-title: N Engl J Med – volume: 71 start-page: 1253 issue: 4 year: 2011 end-page: 62 article-title: Antigen spreading contributes to MAGE vaccinationinduced regression of melanoma metastases publication-title: Cancer Res – volume: 126 start-page: 3036 issue: 8 year: 2016 end-page: 52 article-title: Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape publication-title: J Clin Invest – volume: 17 start-page: 925 issue: 9 year: 2020 end-page: 39 article-title: Cancer immunotherapywith gd T cells: many paths ahead of us publication-title: Cell Mol Immunol – volume: 86 start-page: 1159 issue: 15 year: 1994 end-page: 66 article-title: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 publication-title: J Natl Cancer Inst – volume: 6 start-page: 605 issue: 5 year: 2018 end-page: 16 article-title: Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager publication-title: Cancer Immunol Res – volume: 32 start-page: 1059 issue: 5 year: 2012 end-page: 70 article-title: Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling publication-title: J Clin Immunol – volume: 348 start-page: 62 issue: 6230 year: 2015 end-page: 8 article-title: Adoptive cell transfer as personalized immunotherapy for human cancer publication-title: Science (80-) – volume: 119 start-page: 4133 issue: 18 year: 2012 end-page: 41 article-title: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning publication-title: Blood – volume: 319 start-page: 1676 issue: 25 year: 1988 end-page: 80 article-title: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma publication-title: A preliminary report. N Engl J Med – volume: 132 start-page: 110873 issue: August year: 2020 article-title: Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully publication-title: Biomed Pharmacother – volume: 9 start-page: eaaa0984 issue: 399 year: 2017 article-title: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma publication-title: Sci Transl Med – volume: 34 start-page: 1112 issue: 10 year: 2016 end-page: 21 article-title: Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease publication-title: J Clin Oncol – volume: 126 start-page: 3814 issue: 10 year: 2016 end-page: 26 article-title: Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies publication-title: J Clin Investig – volume: 7 start-page: 737 issue: 1 year: 2017 article-title: CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells publication-title: Sci Rep – volume: 14 start-page: 357 year: 2016 end-page: 62 article-title: Catch me if you can: leukemia Escapeafter CD19-Directed T Cell Immunotherapies publication-title: Comput Struct Biotechnol J – volume: 11 start-page: 1217 year: 2020 article-title: Next-generation manufacturing protocols enriching T SCM CAR T cells can overcome disease-specific T cell defects in cancer patients publication-title: Front Immunol – volume: 29 start-page: 917 issue: 7 year: 2011 end-page: 24 article-title: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 publication-title: J Clin Oncol – volume: 344 start-page: 641 issue: 6184 year: 2014 end-page: 5 article-title: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer publication-title: Science – volume: 25 start-page: 1486 issue: 5 year: 2019 end-page: 93 article-title: A Phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers publication-title: Clin Cancer Res – volume: 5 start-page: 177ra38 issue: 177 year: 2013 article-title: CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia publication-title: Sci Transl Med – start-page: 619 end-page: 31 article-title: Role of melanomaassociated antigens publication-title: From Melanocytes to Melanoma Progress to Malig – volume: 8 start-page: 1 issue: 4 year: 2020 end-page: 22 article-title: Gene augmentation and editing to improve tcr engineered t cell therapy against solid tumors publication-title: Vaccines – volume: 40 start-page: 3395 issue: 6 year: 2020 end-page: 400 article-title: Tumor-infiltrating lymphocyte score based on FDG PET/ CT for predicting the effect of neoadjuvant chemotherapy in breast cancer publication-title: Anticancer Res – volume: 2 start-page: 112 issue: 2 year: 2014 end-page: 20 article-title: Mesothelin-specific chimeric antigen receptor mRNAengineered T cells induce anti-tumor activity in solid malignancies publication-title: Cancer Immunol Res – volume: 77 start-page: 640 issue: 9 year: 1999 end-page: 55 article-title: Human tumor antigens: implications for cancer vaccine development publication-title: J Mol Med – volume: 176 start-page: 139 issue: 3 year: 2017 end-page: 48 article-title: Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know publication-title: Physiol Behav – volume: 10 start-page: 128 year: 2019 article-title: CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment publication-title: Front Immunol – volume: 5 start-page: 571 issue: 7 year: 2017 end-page: 81 article-title: Transgenic expression of IL15 improves antiglioma activity of IL13Ra2-CAR T cells but results in antigen loss variants publication-title: Cancer Immunol Res – volume: 12 start-page: 718 issue: 6 year: 2016 end-page: 29 article-title: New strategies for the treatment of solid tumors with CAR-T cells publication-title: Int J Biol Sci – volume: 21 start-page: 1019 issue: 5 year: 2015 end-page: 27 article-title: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response publication-title: Clin Cancer Res – volume: 30 start-page: v683 issue: suppl_5 year: 2019 end-page: 709 article-title: ADP-A2M4 (MAGE-A4) in patients with Synovial Sarcoma publication-title: Ann Oncol – start-page: 15 year: 2019 article-title: Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma publication-title: J Clin Oncol |
| SSID | ssib030985322 ssib044738437 ssj0002013794 |
| Score | 2.161631 |
| SecondaryResourceType | review_article |
| Snippet | The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the... ABSTRACT The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival... |
| SourceID | doaj scielo pubmedcentral proquest crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | S78 |
| SubjectTerms | Adoptive cell therapy CAR-T cells Cell therapy Checkpoint inhibitors Immunotherapy MEDICINE, GENERAL & INTERNAL Review |
| Title | Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2531137921001474 https://dx.doi.org/10.1016/j.htct.2021.09.011 https://www.proquest.com/docview/2599180145 https://pubmed.ncbi.nlm.nih.gov/PMC8606714 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792021000500078&lng=en&tlng=en https://doaj.org/article/6556afb3af274f31b4fc07c156686c8b |
| Volume | 43 |
| WOSCitedRecordID | wos000721062300012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2531-1387 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002013794 issn: 2531-1379 databaseCode: DOA dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD customDbUrl: eissn: 2531-1387 dateEnd: 99991231 omitProxy: false ssIdentifier: ssib044738437 issn: 2531-1379 databaseCode: M~E dateStart: 20180101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELag6oELAgFi-amMhMQBAvHGjmNutGrVA1RIFLQ3y3ZsNdU2qZIsUi-8DAd4j74YM3FSdkGiFy5Rskm8sefz_CQznwl5XpS-UJKJJBgrEi4tSwzYtWRug8-5AQs9kPp8eS-PjorFQn1cW-oLc8IiPXAcuDe5ELkJNjMB4qeQMcuDS6XDsKPIXWFR-6ZSrQVTgKQsVWCGfhPTcS6zgg8EmnMAXcIyqcYKmpjsddI7TKycs4H0lLENKzWQ-W8YqzVn9M9Uym20XMt1I3Vwh9wevUv6LvbqLrnh63vk5yiCyx-X3xu625oONEHVGlp6eoiUrYP-M6_-OmiwOvm8MtTT43Fvzy8xb5XiOp-4SEZHm5oCBmMp5PKCnjVlFcCtpfhFoHtN47cHOo7zW2xgSWPR1wWtagrQr0rar86atrtPPh_sH-8dJuMCDYkTmeoTljuvAs9BJ3DLrRXIPBlynwdhA3PSlNJ7yZTMXBqUHF56MQseRZk6L4zLHpCtuqn9Q0KDzeFCZxwvkYMQ1EiwhXWiSC3IUZUz8nISiD6PPBx6SlA71Sg-jeLTqdIgvhnZRZldXYkc2sMPgCw99lhfh6wZySaJ66lMFRQrNFT986_F1V2jExOdk2vvezaBSsMMRyGZ2jerTkOAqhiS_IgZkRto2-jf5pm6Ohm4wgsIUCXjM_Ii4lKPKqrTn3AmaJwJ-BQDERD6i4_-x9A9Jrew0Viz-YRs9e3KPyXb7mtfde0OuSkXxc4wYWH74dv-LyY3RbM |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Associa%C3%A7%C3%A3o+Brasileira+de+Hematologia%2C+Hematologia%2C+Hemoterapia+e+Terapia+Celular+Consensus+on+genetically+modified+cells.+Review+article%3A+Cell+therapy+in+solid+tumors&rft.jtitle=Hematology%2C+Transfusion+and+Cell+Therapy&rft.au=Nardo%2C+Mirella&rft.au=Motta%2C+Tatiane+C.&rft.au=Colli%2C+Leandro+M.&rft.au=Avanzi%2C+Mauro+P.&rft.date=2021-11-01&rft.pub=Elsevier+Espa%C3%B1a%2C+S.L.U&rft.issn=2531-1379&rft.volume=43&rft.spage=S78&rft.epage=S83&rft_id=info:doi/10.1016%2Fj.htct.2021.09.011&rft.externalDocID=S2531137921001474 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2531-1379&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2531-1379&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2531-1379&client=summon |